Home・Akcijų sąrašas・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

20.01 3.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.32

Max

20.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M -43M
Pardavimai	-3.6M 65M
Pelnas, tenkantis vienai akcijai	-0.48
Pelno marža	-65.788
Darbuotojai	298
EBITDA	-16M -31M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+92.02% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-02

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-147M 1.7B
Ankstesnė atidarymo kaina	16.92
Ankstesnė uždarymo kaina	20.01

Naujienos nuotaikos

By Acuity

80%

20%

315 / 340 reitingas Healthcare

Syndax Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-06 19:36; UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

2026-08-05 20:02; UTC

News

Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

2026-08-04 23:11; UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

2026-08-03 19:16; UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

2026-07-31 20:06; UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

2026-07-30 17:06; UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

2026-07-29 19:56; UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

2026-07-28 20:51; UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

2026-07-27 20:06; UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

2026-07-24 19:52; UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

2026-07-22 19:06; UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Syndax Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

92.02% į viršų

12 mėnesių prognozė

Vidutinis 38.25 USD 92.02%

Aukščiausias 57 USD

Žemiausias 26 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Syndax Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Syndax Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

315 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.